Slide 1: Q3 and 9M 2018 Results
Q3 and 9M 2018 Results DIASORIN SPA November 7, 2018
Slide 2: Disclaimer
Disclaimer These statements are related, among others, to the intent, belief or current expectations of the customer base, estimates regarding future growth in the different business lines and the global business, market share, financial results and other aspects of the activities and situation rela
Slide 3: Highlights
Highlights COMPANY GUIDANCE Q3’18 9M’18 @ curr @ CER @ curr @ CER FY 2018 REVENUES €/mln 162.8 (*) +9.0% +9.5% €/mln 494.0 (*) +5.4% +9.1% REVENUES ~ +9% at CER vs 2017 (°) (°) Eventual postponement to 2019 of certain large tenders to countries served through distributors CLIA EX VIT D 25 OH +8.7% +
Slide 4: Q3 and 9M 2018 revenues growth
Q3 and 9M 2018 revenues growth Q3’18 vs. Q3’17 9M’18 vs. 9M’17 Q3’18 vs. Q3’17 9M’18 vs. 9M’17 Total Group revenues @ curr +9.0% +5.4% EUROPE & AFRICA +12.5% +14.3% Growth driven by CLIA ex Vitamin D tests and Siemens’ @ CER +9.5% +9.1% Germany +22.6% +22.7% ELISA business acquisition. Negative cont
Slide 5: 9M 2018 revenues breakdown
9M 2018 revenues breakdown by geography by technology Instruments & other revenues 9M’17 9M’17 North America 12.0% 31.8% Molecular diagnostic tests Europe & Africa 8.5% 42.7% CLIA tests 67.4% ELISA tests 12.1% Asia Pacific 18.1% Latin America 7.4% 9M’18 (*) 9M’18 (*) Instruments & other revenues Nor
Slide 6: Installed base expansion
Installed base expansion 7,398 7,501 7,623 7,734 +367 3,518 +116 3,634 +123 3,757 +128 3,885 LAS 3,880 -13 3,867 -1 3,866 -17 3,849 -31 @ Dec 31, 2017 @ March 31, 2018 @ June 30, 2018 @ Sept 30, 2018 Q3 and 9M 2018 Results 6
Slide 7: Q3 and 9M 2018 profitability profile
Q3 and 9M 2018 profitability profile Q3’17 Q3’18 Change % 9M’17 9M’18 Change % EBITDA (€/MLN) 56.0 58.9 +5.3% 182.2 187.1 +2.7% @ CER +6.8% +7.5% EBITDA MARGIN 37.5% 36.2% -128 bps 38.9% 37.9% -99 bps @ CER 36.5% -100 bps 38.3% -60 bps 9M’18 EBITDA upward compared to 9M’17 notwithstanding: • some on
Slide 8: Financial schemes
Financial schemes 8
Slide 9: Income Statement
Income Statement Q3 Change 9M Change Data in € million 2017 2018 amount % 2017 2018 amount % Net revenues 149.4 162.8 +13.4 +9.0% 468.6 494.0 +25.3 +5.4% Gross profit 100.5 109.2 +8.7 +8.6% 319.7 336.0 +16.3 +5.1% Gross Margin 67.3% 67.1% -21 bps 68.2% 68.0% -20 bps S&M (29.7) (32.2) -2.5 +8.4% (89.
Slide 10: Balance Sheet
Balance Sheet Data in € million 12/31/17 09/30/18 Change Goodwill and intangibles assets 344.4 355.8 +11.4 Property, plant and equipment 92.3 92.9 +0.5 Other non-current assets 23.8 24.8 +1.0 Net working capital 190.7 215.2 +24.5 Assets held for sale 4.0 - -4.0 Other non-current liabilities (62.5) (
Slide 11: Cash Flow Statement
Cash Flow Statement Q3 9M Data in € million Change Change 2017 2018 2017 2018 Cash and cash equivalents at the beginning of the period 107.9 104.6 -3.3 130.5 159.3 +28.9 Operating activities 48.9 45.0 -4.0 125.9 133.4 +7.5 Investing activities (13.0) (14.1) -1.1 (30.1) (35.1) -5.0 Financing activiti
Slide 12: Slide 12